Monthly News Roundup - September 2024

FDA Approves Ocrevus Zunovo, a Twice-A-Year Subcutaneous Injection for Relapsing and Progressive Multiple Sclerosis
In September, Genentech announced the approval of Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq), a subcutaneous (SC) injection...